In a huge boost for the Made in India vision, and mission, the World Health Organization has now approved Bharat Biotech’s Covaxin vaccine for all people, except pregnant women.
This means that any Indian citizen who has administered Covaxin vaccine is eligible to travel to any country, based on the WHO rules.
More details right here.
Covaxin Vaccine Now WHO-Approved
In a big, positive move for Bharat Biotech and the Indian Council of Medical Research who made the Covaxin vaccine, World Health Organization has approved its usage.
All citizens who are above 18 years, except pregnant women, can now take the Covaxin vaccine, and travel to any nation where WHO-approved double dose of Covid vaccine is mandated.
The approval came in after the technical advisory group of WHO approved the usage of the vaccine after due tests and examinations.
At the tests and research, Covaxin vaccine was found to have 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant.
Which Vaccines Are Now WHO-Approved?
Along with Covaxin vaccine, WHO has approved these Covid-19 vaccine for emergency usage for all 18+ humans (except pregnant women in some cases):
Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson 7 Johnson – Janssen, Moderna, and Sinopharm.
In India, only Covishield vaccine made by AstraZeneca-SK Bio/Serum Institute of India was WHO-approved, and this causes much problems for those who had taken Cavaxin vaccine, and wishes to travel abroad.
WHO said, “WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the #Covaxin vaccine meets WHO standards for protection against #COVID19, that the benefit of the vaccine far outweighs risks & the vaccine can be used. #Covaxin vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above. Available data on vaccination of pregnant women with the #Covaxin vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry,”
We will keep you updated, as more details come in.
Comments are closed, but trackbacks and pingbacks are open.